Britain secures 90 million possible COVID-19 vaccine doses from Pfizer/BioNTech, Valneva
By Alistair Smout LONDON (Reuters) - Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc and BioNTech, and French group Valneva, the business ministry said on Monday.
COVID-19 vaccine doses from Pfizer/BioNTech, Valneva" src="https://images.firstpost.com/wp-content/uploads/reuters/07-2020/21/2020-07-20T164203Z_2_LYNXNPEG6J0AZ_RTROPTP_2_HEALTH-CORONAVIRUS-CHINA-VACCINE.jpg" alt="Britain secures 90 million possible COVID19 vaccine doses from PfizerBioNTech Valneva" width="300" height="225" />
By Alistair Smout
LONDON (Reuters) - Britain has signed deals to secure 90 million doses of two possible COVID-19 vaccines from an alliance of Pfizer Inc and BioNTech, and French group Valneva, the business ministry said on Monday.
Britain secured 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of the Valneva vaccine, with an option of 40 million more doses if it was proven to be safe, effective and suitable, the ministry said.
With no working vaccine against COVID-19 yet developed, Britain now has three different types of vaccine under order and a total of 230 million doses potentially available.
"This new partnership with some of the world's foremost pharmaceutical and vaccine companies will ensure the UK has the best chance possible of securing a vaccine that protects those most at risk," business minister Alok Sharma said.
Financial terms were not disclosed.
The deals follow a previously announced agreement with AstraZeneca for the firm to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford.
Britain said it was the first such deal which Pfizer and BioNTech had agreed for the supply of their vaccine, which is being tested in early to mid stage trials.
The firms are aiming to make up to 100 million doses by the end of this year and potentially more than 1.2 billion doses by end of 2021, if the vaccine is successful.
It uses the so-called messenger RNA approach, in contrast to the more traditional, inactivated whole virus vaccine being developed by Valneva.
Valneva's potential vaccine is still in pre-clinical trials, and the company is aiming to move into clinical trials by the end of 2020.
Britain also said on Monday it had secured treatments containing COVID-19 -neutralising antibodies from AstraZeneca to protect people who can't be vaccinated.
(Reporting by Alistair Smout; Editing by Richard Pullin and Peter Graff)
This story has not been edited by Firstpost staff and is generated by auto-feed.
(Reuters) - Alphabet Inc's self-driving unit Waymo said on Thursday it had partnered with Google's Maps to let users book fully autonomous ride-hailing services through the app.
FRANKFURT (Reuters) - Tesla on Thursday revised its application for a planned gigafactory in Europe to include details for plans to produce battery cells on site and an expansion of other production lines, German officials said. It also includes plans to reduce water consumption so that usage remains constant compared to earlier proposals despite the expansion. Tesla has sharply criticised the lengthy regulatory processes in Germany and has pushed back the factory's opening date.
By Mathieu Rosemain PARIS (Reuters) - U.S. social media giant Facebook has offered to commit to providing its partners with clear and objective conditions of access to advertising inventories and ad campaign data, France's antitrust authority said on Thursday following an investigation.